# Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

> **NCT01573624** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 421 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/GSK573719
- **DRUG:** FF/GSK573719
- **DRUG:** FF/GSK573719
- **DRUG:** FF/GSK573719
- **DRUG:** FF/GSK573719
- **DRUG:** FF
- **DRUG:** FF/VI

## Key facts

- **NCT ID:** NCT01573624
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-03
- **Primary completion:** 2013-02-04
- **Final completion:** 2013-02-04
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01573624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01573624, "Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01573624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*